 Zynerba Pharmaceuticals NASDAQ:ZYNE Inc has announced very encouraging data from a trial of its Zygel CBD gel for the treatment of 22q11.2 Deletion Syndrome 22q. The exploratory, open-label Phase 2 INSPIRE trial was designed for signal detection by assessing the safety, tolerability and efficacy of Zygel also known as ZYN002 for the treatment of behavioral symptoms of 22q in children and adolescents. 